Nanodiamond particles and related devices and methods, such as nanodiamond particles for the detection and/or quantification of analytes, are generally described. In some embodiments, the device comprises a plurality of nanodiamond particles and a species bound to the nanodiamond particles. In certain embodiments, the plurality of nanodiamond particles may be exposed to a sample suspected of containing an analyte. In some cases, the analyte may bind to the species such that the presence of the analyte in the sample may be detected. In some embodiments, the devices, systems, and methods described herein are useful for the detection of an analyte in a sample obtained from a subject for, for example, diagnostic purposes. In some cases, the systems, devices, and methods described herein may be useful for diagnosing, prevent, treating, and/or managing a disease or bodily condition. In an exemplary embodiment, such systems, devices, and methods described herein may be useful for detecting and/or quantifying the presence of a virus (e.g., ebola) in a subject and/or a sample obtained from the subject.

The present invention relates to a method for assaying D-dimers that are specific to venous thromboembolism, resulting from the degradation of intravascular fibrin in a blood sample, including routine assay of D-dimers contained in the sample and dynamic measurement of fibrin formation in same. This method may be used to rule out pulmonary embolism or deep venous thrombosis in patients and/or to diagnose thrombosis or coagulation activation or thrombophilia in patients.

Provided herein are methods for the diagnosis, prognosis, and treatment of thrombosis in subject having or suspected of having systemic lupus erythematosus including determination of a level of platelet-bound complement C4d, C3 level, and one or both of a level of antiphosphatidyl serine/prothrombin complex and/or lupus anticoagulant.

Nanodiamond particles and related devices and methods, such as nanodiamond particles for the detection and/or quantification of analytes, are generally described. In some embodiments, the device comprises a plurality of nanodiamond particles and a species bound to the nanodiamond particles. In certain embodiments, the plurality of nanodiamond particles may be exposed to a sample suspected of containing an analyte. In some cases, the analyte may bind to the species such that the presence of the analyte in the sample may be detected. In some embodiments, the devices, systems, and methods described herein are useful for the detection of an analyte in a sample obtained from a subject for, for example, diagnostic purposes. In some cases, the systems, devices, and methods described herein may be useful for diagnosing, prevent, treating, and/or managing a disease or bodily condition. In an exemplary embodiment, such systems, devices, and methods described herein may be useful for detecting and/or quantifying the presence of a virus (e.g., ebola) in a subject and/or a sample obtained from the subject.

Disclosed are methods of treating venous thromboembolism (VTE) in a subject, the method comprising administering a venous thrombus size lowering therapy to the subject, wherein the venous thrombus size lowering therapy is a plasminogen activator inhibitor 1 (PAI-1) inhibitor. Disclosed are methods of diagnosing and VTE, the method comprising diagnosing the subject as being at greater risk of developing VTE; and administering a venous thrombus size lowering therapy to the subject, wherein the venous thrombus size lowering therapy is a PAI-1 inhibitor. Disclosed are methods of determining a PRS for developing VTE in a subject comprising identifying the presence of one or more of the 297 SNPs identified in FIG. 19 are present in a biological sample from the subject; and calculating the PRS by summing the weighted risk score associated with each SNP identified.

Described are mutant Platelet Factor 4 (PF4) proteins that exhibit different binding affinities to vaccine induced immune thrombotic thrombocytopenia (VITT) antibodies or non-heparin-induced thrombocytopenia (non-HIT) antibodies relative to heparin-induced thrombocytopenia (HIT) antibodies. Also provided herein are methods for differentiating between VITT, HIT, and/or non-HIT in subjects suspected of having VITT, HIT, or non-HIT.

Disclosed are methods and systems for the analysis activity of enzyme disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in a sample. The methods and systems disclosed herein can be useful for diagnosis of thrombotic thrombocytopenic purpura in a patient.

Compositions and methods for regulating the blood coagulation pathway are disclosed. More particularly, the present disclosure relates to thrombin-thrombomodulin fusion proteins, vectors, host cells and methods for preparing the thrombin-thrombomodulin fusion proteins. The present disclosure further relates to methods for measuring protein C in plasma and kits for measuring protein C in plasma.

Disclosed are methods and systems for the analysis activity of enzyme disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in a sample. The methods and systems disclosed herein can be useful for diagnosis of thrombotic thrombocytopenic purpura in a patient.

Disclosed are drugs capable of inhibiting the complement pathway for use for treating hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy (HSCT-TMA, also called TA-TMA) in a subject that has undergone an HSCT. Also disclosed are methods of using drugs capable of inhibiting the complement pathway for use for treating hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy (HSCT-TMA) in a subject that has undergone an HSCT.